Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcomaAviv Regev, Cyril Neftel, Marni E. Shore et al.|Nature Medicine|2021Cited by 127
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3John D. Powderly, Bartosz Chmielowski, Jan Baughman et al.|Journal for ImmunoTherapy of Cancer|2015Cited by 101
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)Brigitte C. Widemann, John P. Perentesis, Yao Lu et al.|Sarcoma|2019Cited by 74
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological CorrelatesCandace L. Haddox, Suzanne George, Michael J. Nathenson et al.|Clinical Cancer Research|2024Cited by 35
Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological CorrelatesCandace L. Haddox, Suzanne George, Michael J. Nathenson et al.|Unknown|2024Cited by 1